KMT2A and T-cell acute lymphoblastic leukemia: Moreover, with regard to hematological malignancies, RG7112 showed a significant antitumor activity against ALL xenografts including B cell precursor acute lymphoblastic leukemia (BCP-ALL), T cell acute lymphoblastic leukemia (T-ALL), and MLL-ALL with the most impressive effect reported on infant MLL-rearranged xenograft when RG7112 was used either alone or in combination with established drugs such as vincristine, dexamethasone, and l-asparaginase [85, 132].